Cue Biopharma is trading 5.1% lower at $19.80, with biotech-sector pressure potentially contributing to the decline. - No clear company-specific announcement explaining the November 2, 2026 decline surfaced in the latest company-news results; the prominent CUE-221 Phase 2 update is dated September, not November 2. - The provided sector context shows biotech stocks down 2.39%, while available early XBI data showed a smaller decline; sector pressure is not a conclusive explanation.